271 related articles for article (PubMed ID: 20919852)
1. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH; Artz AS; Undevia SD; Pai RK; Del Cerro P; Horowitz S; Godley LA; Hart J; Innocenti F; Larson RA; Odenike OM; Stock W; Van Besien K
Leuk Lymphoma; 2010 Dec; 51(12):2240-9. PubMed ID: 20919852
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
Pai RK; van Besien K; Hart J; Artz AS; O'Donnell PH
Leuk Lymphoma; 2012 Aug; 53(8):1552-7. PubMed ID: 22280517
[TBL] [Abstract][Full Text] [Related]
3. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
[TBL] [Abstract][Full Text] [Related]
4. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
5. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
[TBL] [Abstract][Full Text] [Related]
6. Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.
Shimoni A; Nagler A
Leuk Lymphoma; 2010 Dec; 51(12):2154-6. PubMed ID: 21133737
[No Abstract] [Full Text] [Related]
7. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
Shea TC; Walko C; Chung Y; Ivanova A; Sheets J; Rao K; Gabriel D; Comeau T; Wood W; Coghill J; Armistead P; Sarantopoulos S; Serody J
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2129-2135. PubMed ID: 26210442
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.
Ohwada C; Yamazaki S; Shono K; Kayamori K; Hino Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Iseki T; Onoda M; Yokota A; Suzuki T; Ishii I; Nakaseko C; Sakaida E
Int J Hematol; 2021 Dec; 114(6):664-673. PubMed ID: 34523110
[TBL] [Abstract][Full Text] [Related]
10. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
11. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
de Lima M; Couriel D; Thall PF; Wang X; Madden T; Jones R; Shpall EJ; Shahjahan M; Pierre B; Giralt S; Korbling M; Russell JA; Champlin RE; Andersson BS
Blood; 2004 Aug; 104(3):857-64. PubMed ID: 15073038
[TBL] [Abstract][Full Text] [Related]
12. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
13. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
[TBL] [Abstract][Full Text] [Related]
14. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
15. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
Mohty M; Malard F; Blaise D; Milpied N; Furst S; Tabrizi R; Guillaume T; Vigouroux S; El-Cheikh J; Delaunay J; Le Gouill S; Moreau P; Labopin M; Chevallier P
Cancer; 2015 Feb; 121(4):562-9. PubMed ID: 25283774
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
18. Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen.
Huang J; Li Z; Liang W; Chen B; Hu J; Yang W
J Clin Pharmacol; 2019 May; 59(5):638-645. PubMed ID: 30512187
[TBL] [Abstract][Full Text] [Related]
19. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
